03/17/2026
🚨 The FDA’s recent GLP-1 crackdown isn’t just about marketing, it’s raising questions about how these programs are prescribed.
After issuing 30 warning letters to telehealth companies, the FDA cited misleading claims around compounded GLP-1 drugs.
But the enforcement action is also drawing attention to how these programs are structured behind the scenes.
Many telehealth GLP-1 platforms do not prescribe medications directly.
Instead, they rely on clinicians in affiliated medical groups to evaluate patients and issue prescriptions.
These models often involve multiple layers:
➡️ Telehealth platform
➡️ Affiliated medical group
➡️ Prescribing clinician
➡️ Compounding pharmacy
That structure can create gaps in oversight and accountability.
Clinics participating in these programs should ensure:
✔️ Clear accountability between platform, prescriber, and clinic
✔️ Telehealth evaluations meet state-specific requirements
✔️ Marketing reflects how care is actually delivered
✔️ Proper documentation of clinical eligibility and patient care
As regulators increase scrutiny, GLP-1 programs are being evaluated not just on what is marketed, but how care is delivered and prescribed.
💡 Follow Spakinect for compliance insights designed specifically for Med Spa owners.